Defilade Capital Management L.P. trimmed its stake in Eli Lilly and Company (NYSE:LLY – Free Report) by 35.2% during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 20,696 shares of the company’s stock after selling 11,254 shares during the quarter. Eli Lilly and Company makes up 2.7% of Defilade Capital Management L.P.’s holdings, making the stock its 17th largest holding. Defilade Capital Management L.P.’s holdings in Eli Lilly and Company were worth $19,036,000 as of its most recent filing with the Securities & Exchange Commission.
Other institutional investors and hedge funds also recently modified their holdings of the company. S&A Financial Services Inc. acquired a new position in shares of Eli Lilly and Company in the 1st quarter valued at $391,000. LFG Wealth Partners LLC increased its stake in Eli Lilly and Company by 2.3% in the 1st quarter. LFG Wealth Partners LLC now owns 2,269 shares of the company’s stock worth $2,087,000 after purchasing an additional 51 shares in the last quarter. Curry Webb Wealth Management LLC acquired a new stake in Eli Lilly and Company during the 1st quarter worth about $1,974,000. FAS Wealth Partners Inc. raised its holdings in Eli Lilly and Company by 3.5% during the 1st quarter. FAS Wealth Partners Inc. now owns 10,415 shares of the company’s stock worth $9,579,000 after buying an additional 350 shares during the period. Finally, Rathbones Group PLC lifted its stake in Eli Lilly and Company by 6.6% during the first quarter. Rathbones Group PLC now owns 418,036 shares of the company’s stock valued at $384,497,000 after buying an additional 25,882 shares in the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.
Eli Lilly and Company Stock Up 0.0%
LLY stock opened at $1,149.28 on Monday. The company has a 50 day moving average of $1,152.66 and a two-hundred day moving average of $1,043.90. The company has a market cap of $1.08 trillion, a price-to-earnings ratio of 40.83, a PEG ratio of 1.43 and a beta of 0.51. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $1,249.45. The company has a quick ratio of 1.10, a current ratio of 1.50 and a debt-to-equity ratio of 1.26.
Eli Lilly and Company Announces Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, September 10th. Investors of record on Friday, August 14th will be given a dividend of $1.73 per share. The ex-dividend date of this dividend is Friday, August 14th. This represents a $6.92 dividend on an annualized basis and a yield of 0.6%. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 24.58%.
Eli Lilly and Company News Summary
Here are the key news stories impacting Eli Lilly and Company this week:
- Positive Sentiment: Lilly continues to pull ahead of Novo Nordisk in the rapidly expanding obesity-treatment market, with significantly stronger recent revenue growth and a more favorable outlook. Lilly’s latest reported quarter included 55.5% year-over-year revenue growth, while Novo Nordisk expects an adjusted sales decline. Eli Lilly Stock Has Skyrocketed. Novo Nordisk Has Crashed.
- Positive Sentiment: The company is investing another $750 million with Resilience to expand U.S. manufacturing capacity for diabetes and obesity medicines. The project is expected to add at least 400 jobs and supports Lilly’s ability to meet continued demand. Lilly Boosts Diabetes and Obesity Capacity With $750 Million Deal
- Positive Sentiment: Completion of a late-stage retatrutide trial provides a potential future catalyst in diabetes, obesity and related cardiovascular indications. Lilly has also begun an early-stage study of eloralintide, adding another candidate to its weight-loss pipeline. Lilly’s Retatrutide Trial Completion Signals Next Wave in Diabetes and Obesity Drugs
- Neutral Sentiment: Analysts are focused on key operating metrics for Lilly’s second-quarter results, including demand, prescription trends and guidance. The company’s prior earnings report substantially exceeded estimates, raising expectations for the upcoming release. Lilly Q2 Earnings on the Horizon
- Negative Sentiment: Weight-loss drug stocks came under pressure as investors digested clinical-trial news and positioned ahead of earnings. Technical selling intensified after Lilly fell below a closely watched support level, despite its stronger long-term fundamentals. Weight Loss Drug Stocks Slump
Analyst Ratings Changes
LLY has been the subject of several recent analyst reports. Wolfe Research reiterated an “outperform” rating and issued a $1,350.00 target price on shares of Eli Lilly and Company in a report on Thursday, May 21st. Royal Bank Of Canada upped their price target on shares of Eli Lilly and Company from $1,250.00 to $1,500.00 and gave the company an “outperform” rating in a research report on Wednesday, July 8th. JPMorgan Chase & Co. raised their price objective on shares of Eli Lilly and Company from $1,300.00 to $1,400.00 and gave the stock an “overweight” rating in a research note on Tuesday, July 7th. Jefferies Financial Group raised their target price on Eli Lilly and Company from $1,330.00 to $1,350.00 and gave the stock a “buy” rating in a research report on Tuesday, June 9th. Finally, Barclays lifted their price target on Eli Lilly and Company from $1,350.00 to $1,400.00 and gave the company an “overweight” rating in a report on Monday, May 4th. Two research analysts have rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $1,283.64.
View Our Latest Research Report on Eli Lilly and Company
Eli Lilly and Company Profile
Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.
Featured Articles
- Five stocks we like better than Eli Lilly and Company
- 3 Fixed-Income ETFs Show Why Yield Is Only Part of the Income Story
- AbbVie Quietly Solved Its Biggest Problem—Now What?
- Rio Tinto’s Results Make the Case for Looking Beyond Tech in the AI Trade
- Strategy’s Structural Strength: Hidden in a $8 Billion Illusion
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.
